Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with 68Ga-PSMA-11 PET/MRI in men with treatment-naive prostate cancer

被引:48
作者
Ettala, Otto [1 ,2 ]
Malaspina, Simona [2 ,3 ,4 ]
Tuokkola, Terhi [2 ,4 ]
Luoto, Pauliina [2 ,4 ]
Loyttyniemi, Eliisa [5 ]
Bostrom, Peter J. [1 ,2 ]
Kemppainen, Jukka [2 ,3 ,4 ]
机构
[1] Univ Turku, Dept Urol, Turku, Finland
[2] Turku Univ Hosp, Turku, Finland
[3] Univ Turku, Dept Clin Physiol & Nucl Med, Turku, Finland
[4] Univ Turku, Turku PET Ctr, Turku, Finland
[5] Univ Turku, Dept Biostat, Turku, Finland
关键词
Prostate cancer; PSMA; PET; androgen deprivation therapy; ADT; POSITRON-EMISSION-TOMOGRAPHY; MEMBRANE ANTIGEN; FLARE; PET;
D O I
10.1007/s00259-019-04635-7
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose Based on in vitro studies, it is known that androgen deprivation therapy (ADT) increases prostate-specific membrane antigen (PSMA) expression. Therefore, we hypothesised that ADT improves the performance of PSMA-PET imaging in primary staging of prostate cancer. The purpose of the study was to demonstrate the time course effect of ADT on PSMA uptake in different types of metastatic lesions evaluated with Ga-68-PSMA-11 PET/MRI. Methods Nine men with treatment-naive prostate cancer were enrolled to a prospective, registered (NCT03313726) clinical trial. A Ga-68-PSMA-11 PET/MRI was performed once before and 3 times post-ADT (degarelix, Firmagon). Change of maximum standardised uptake values (SUVmax) in prostate, lymph nodes, bone metastases, and physiologically PSMA-avid organs were evaluated in a time frame of 1-8 weeks. Results All patients reached castration levels within 10 days, and 50% decrease in prostate-specific antigen (PSA) concentration was observed 14 days post-ADT. A heterogeneous increase in PSMA uptake was observed 3 to 4 weeks post-ADT. This phenomenon was definitively more evident in bone metastases: 13 (57%) of the metastasis, with a mean (range) SUVmax increase of 77% (8-238%). In one patient, already having bone metastases at baseline, three new bone metastases were observed post-ADT. Of lesions with reduced SUVmax, none disappeared. Conclusions Both in patient and region level, increase in PSMA uptake post-ADT is heterogenous and is seen most evidently in bone metastases. Preliminary results on a small cohort of patients suggest the clinical impact of ADT on improving the performance of Ga-68-PSMA PET in staging seems to be minor. However, the optimal imaging time point might be 3 to 4 weeks post-ADT. Since none of the metastases with decreasing SUVmax disappeared, it seems that short-term usage of ADT does not interfere with the interpretation of Ga-68-PSMA PET.
引用
收藏
页码:665 / 673
页数:9
相关论文
共 22 条
  • [1] PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions
    Afshar-Oromieh, A.
    Malcher, A.
    Eder, M.
    Eisenhut, M.
    Linhart, H. G.
    Hadaschik, B. A.
    Holland-Letz, T.
    Giesel, F. L.
    Kratochwil, C.
    Haufe, S.
    Haberkorn, U.
    Zechmann, C. M.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (04) : 486 - 495
  • [2] Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer
    Afshar-Oromieh, Ali
    Debus, Nils
    Uhrig, Monika
    Hope, Thomas A.
    Evans, Michael J.
    Holland-Letz, Tim
    Giesel, Frederik L.
    Kopka, Klaus
    Hadaschik, Boris
    Kratochwil, Clemens
    Haberkorn, Uwe
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (12) : 2045 - 2054
  • [3] Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer
    Aggarwal, Rahul
    Wei, Xiao
    Kim, Won
    Small, Eric J.
    Ryan, Charles J.
    Carroll, Peter
    Cooperberg, Matthew
    Evans, Michael J.
    Hope, Thomas
    [J]. EUROPEAN UROLOGY ONCOLOGY, 2018, 1 (01): : 78 - 82
  • [4] Performance of 68Ga-PSMA PET/CT for Prostate Cancer Management at Initial Staging and Time of Biochemical Recurrence
    Bailey, Jason
    Piert, Morand
    [J]. CURRENT UROLOGY REPORTS, 2017, 18 (11)
  • [5] Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges
    Bakht M.K.
    Oh S.W.
    Youn H.
    Cheon G.J.
    Kwak C.
    Kang K.W.
    [J]. Nuclear Medicine and Molecular Imaging, 2017, 51 (3) : 202 - 211
  • [6] Post-transcriptional regulation of the androgen receptor by mammalian target of rapamycin
    Cinar, B
    De Benedetti, A
    Freeman, NR
    [J]. CANCER RESEARCH, 2005, 65 (07) : 2547 - 2553
  • [7] 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review
    Corfield, Julia
    Perera, Marlon
    Bolton, Damien
    Lawrentschuk, Nathan
    [J]. WORLD JOURNAL OF UROLOGY, 2018, 36 (04) : 519 - 527
  • [8] Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial 68Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade
    Emmett, Louise
    Yin, Charlotte
    Crumbaker, Megan
    Hruby, George
    Kneebone, Andrew
    Epstein, Richard
    Quoc Nguyen
    Hickey, Adam
    Ihsheish, Noah
    O'Neill, Gordon
    Horvath, Lisa
    Chalasani, Venu
    Stricker, Phillip
    Joshua, Anthony M.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (07) : 950 - 954
  • [9] Consensus on molecular imaging and theranostics in prostate cancer
    Fanti, Stefano
    Minozzi, Silvia
    Antoch, Gerald
    Banks, Ian
    Briganti, Alberto
    Carrio, Ignasi
    Chiti, Arturo
    Clarke, Noel
    Eiber, Matthias
    De Bono, Johann
    Fizazi, Karim
    Gillessen, Silke
    Gledhill, Sam
    Haberkorn, Uwe
    Herrmann, Ken
    Hicks, Rodney J.
    Lecouvet, Frederic
    Montironi, Rodolfo
    Ost, Piet
    O'Sullivan, Joe M.
    Padhani, Anwar R.
    Schalken, Jack A.
    Scher, Howard I.
    Tombal, Bertrand
    van Moorselaar, R. Jeroen A.
    Van Poppel, Heindrik
    Vargas, Hebert Alberto
    Walz, Jochen
    Weber, Wolfgang A.
    Wester, Hans-Jurgen
    Oyen, Wim J. G.
    [J]. LANCET ONCOLOGY, 2018, 19 (12) : E696 - E708
  • [10] 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
    Fendler, Wolfgang P.
    Eiber, Matthias
    Beheshti, Mohsen
    Bomanji, Jamshed
    Ceci, Francesco
    Cho, Steven
    Giesel, Frederik
    Haberkorn, Uwe
    Hope, Thomas A.
    Kopka, Klaus
    Krause, Bernd J.
    Mottaghy, Felix M.
    Schoder, Heiko
    Sunderland, John
    Wan, Simon
    Wester, Hans-Juergen
    Fanti, Stefano
    Herrmann, Ken
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (06) : 1014 - 1024